Sporadic adenomatous polyp regression with exisulind is effective but toxic: A randomised, double blind, placebo controlled, dose-response study

Gut

Volumn 55, Issue 3, 2006, Pages 367-373

  Arber, N ^a,b   Kuwada, S ^c   Leshno, M ^b   Sjodahl, R ^d   Hultcrantz, R ^e   Rex, D ^f  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; LIVER ENZYME; PLACEBO; SULINDAC SULFONE;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACCIDENTAL INJURY; ADENOMATOUS POLYP; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARCINOMA; CHOLECYSTITIS; CHOLELITHIASIS; CLINICAL TRIAL; COLON ADENOMA; COLONOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PANCREATITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIGMOIDOSCOPY; THORAX PAIN;

ADENOMATOUS POLYPOSIS COLI; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COLONOSCOPY; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; SULINDAC; TREATMENT OUTCOME;

EID: 33144470373     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2004.061432     Document Type: Article

References (38)

1. Bond JH. Polyp guideline: diagnosis, treatment, and surveillance for patients with non-familial colorectal polyps: the Practice Parameters Committee of the American College of Gastroenterology. Ann Intern Med 1993;119:836-43.
2. Burt RW, Bishop DT, Lynch HT, et al. Risk and surveillance of individuals with colorectal polyps: WHO Collaborative Centre for the Prevention of Colorectal Cancer. Bull World Health Organ 1990;68:789-95.
3. Colorectal cancer. In: Steward BW, Kleihues P, eds. World cancer report. Lyon: IARC Press, 2003:198-202.
4. Stryker SJ, Wolff BG, Culp CE, et al. Natural history of untreated colonic polyps. Gastroenterology 1987;93:1009-13.
5. Feoron ER. Molecular genetic studies of the adenoma-carcinoma sequence. Adv Intern Med 1994;39:123-30.
6. Chung DC. The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. Gastroenterology 2000;119:854-65.
7. th edn. Philadelphia: Saunders, 1998;1865-912).
8. Anwar S, White J, Hall C, et al. Sporadic colorectal polyps: management options and guidelines. Scand J Gastroenterol 1999;34:4-11.
9. Bond JH. Colorectal cancer update. Prevention, screening, treatment, and surveillance for high-risk groups. Med Clin North Am 2000;84:1163-82.
10. Burt RW. Colon cancer screening. Gastroenterology 2000;119:837-53.
11. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer in colonoscopic polypectomy. N Engl J Med 1993;329:1977-81.
12. Williams CS, Smalley W, DuBois RN. Aspirin use and potential mechanisms for colorectal cancer prevention. J Clin Invest 1997;100:1325-9.
13. Ahnen DJ. Colon cancer prevention by NSAIDs: What is the mechanism of action? Eur J Surg 1998;582(suppl):111-14.
14. Arber N. NSAIDs prevent colorectal cancer. Can J Gastroenterol 2000;14:299-307.
15. Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983;24:83-7.
16. Waddell WR, Ganser GF, Cerise EJ, et al. Sulindac for polyposis of the colon. Am J Surg 1989;157:175-9.
17. Rigau J, Pique JM, Rubio E, et al. Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med 1991;115:952-4.
18. Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomotous polyposis. Gastroenterology 1991;101:635-9.
19. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-16.
20. Hurlimann R, Muller A, Meyenberger C, et al. Regression of adenomas in familial adenomatous polyposis (FAP) is enhanced in the proximal colon by sulindac. Gastroenterology 1994;106:A394.
21. DiSario JA, Alberts DS, Tietze CC, et al. Sulindac induces regression and prevents progression of sporadic colorectal adenomas. Gastrointestinal Oncol 1997;112:A555.
22. Matsuhashi N, Nakajima A, Fukushima Y, et al. Effects of sulindac on sporadic colorectal adenomatous polyps. Gut 1997;40:344-9.
23. Lodenheim J, Garcia G, Titzer D, et al. Effect of sulindac on sporadic colonic polyps. Gastroenterology 1995;108:1083-7.
24. Hixson LJ, Earnest DL, Fennerty MB, et al. NSAID effect on sporadic colon polyps. Am J Gastroenterol 1993;88:1652-6.
25. Hawk E, Prindiville S, Kelloff G. NSAID trials, sporadic adenomas, and conservative inferences. Gastroenterology 1996;110:654.
26. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999;340:1888-99.
27. Goluboff ET. Exisulind, a selective apoptotic antineoplastic drug. Expert Opin Invest Drugs 2001;10:1875-82.
28. Piazza GA, Rahm AK, Finn TS. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res 1997;57:2452-9.
29. Piazza GA, Alberts DS, Hixson LJ, et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 1997;57:2909-15.
30. Thompson WJ, Piazza GA, Li H, et al. Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated β-catenin. Cancer Res 2000;60:3338-42.
31. Van Stolk R, Stoner G, Hayton WL, et al. Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clin Cancer Res 2000;6:78-89.
32. Piazza GA, Xu S, Klein-Szanto, et al. Overexpression of cGMP phosphodiesterase (cG-PDE) in colonic neoplasias compared to normal mucosa. Gastroenterology 2000;118:1590.
33. Burke C. The effect of exisulind on rectal adenomas in adults with familial adenomatous polyposis. Cancer Invest 2000;19:1.
34. Burke C, Van Stolk R, Arber N, et al. Phillips. Exisulind prevents adenoma formation in familial adenomatous polyposis (FAP). Gastroenterology 2000;118:A657.
35. Phillips R, Hultcrantz R, Bjork J, et al. Exisulind, a pro-apoptotic drug, prevents new adenoma formation in patients with familial adenomatous polyposis. Gut 2000;47:A2-3.
36. Engels JM, Diehr P. Imputation of missing longitudinal data: a comparison of methods. J Clin Epidemiol 2003;56:968-76.
37. Bersentes K, Fennerty MB, Sampliner RE, et al. Lack of spontaneous regression of tubular adenomas in two years of follow-up. Am J Gastroenterol 1997;92:1117-20.
38. Loeve F, Boer R, Zauber AG, et al. National Polyp Study data: evidence for regression of adenomas. Int J Cancer 2004;111:633-9.